PharmaShots Weekly Snapshots (April 15 – April 19, 2024)

Share this

PharmaShots Weekly Snapshots (April 15 – April 19, 2024)

This week PharmaShots’ news was all about the updates on Regulatory, Clinical Trials, Pharma, Animal Health & MedTech.

Check out our full report below: 



The US FDA Accepts GSK’s BLA of Meningococcal ABCWY Vaccine for Invasive Meningococcal Disease (IMD)

Read More: GSK                                                                                                              

NovelMed’s NM5072 Receives the US FDA’s Orphan Drug Designation to Treat Paroxysmal Nocturnal Hemoglobinuria (PNH)

Read More:  NovelMed                                                                                               

Sentynl Therapeutics’ Nulibry (fosdenopterin) Gains the MHRA’s Approval to Treat Molybdenum Cofactor Deficiency (MoCD) Type A

Read More: Sentynl Therapeutics                                                                                  

Takeda’s Entyvio Receives the US FDA’s Approval for Subcutaneous Administration to Treat Moderately to Severely Active Crohn’s Disease (CD)

Read More: Takeda 


Nxera Pharma Collaborates with Handok to Commercialize Pivlaz in South Korea

Read More: Nxera Pharma & Handok

Medincell Collaborates with AbbVie for the Development of Therapies Across Various Indications

Read More: Medincell & AbbVie                          

IGM Biosciences Revises its Collaboration with Sanofi

Read More: IGM Biosciences & Sanofi

GV20 Therapeutics Collaborates with Merck to Evaluate GV20-0251 + KEYTRUDA in Patients with Advanced Solid Tumors

Read More: GV20 Therapeutics & Merck

Alvotech and Teva Pharmaceuticals Collaborates to Expand Access for Adalimumab-ryvk (Interchangeable Biosimilar, Humaira) in US

Read More: Alvotech & Teva

Essential Pharma Acquires Reminyl (galantamine hydrobromide) Oral Capsules from Janssen

Read More: Essential Pharma & Reminyl


TELA Bio Launches OviTex IHR to Repair Inguinal Hernia Across the US

Read More: TELA Bio

Shinobi Therapeutics Teams Up with Panasonic to Develop Affordable and Efficient iPS Cell Therapy Manufacturing Technology

Read More: Shinobi Therapeutics & Panasonic


AbbVie Reports Data from the P-III Trial of Atogepant as a Preventive Treatment of Migraine

Read More: AbbVie

Roche Reports Data from the P-III Clinical Evaluation of Columvi to Treat R/R Diffuse Large B-cell Lymphoma 

Read More: Roche 

MaaT Pharma to Highlight Data from the Early Access Program of MaaT013 to Treat Acute Graft-Versus-Host Disease (aGvHD) at EBMT 2024

Read More: MaaT Pharma 

Novartis Reports Data from the P-III Study of Fabhalta (iptacopan) for the Treatment of IgA Nephropathy (IgAN)

Read More: Novartis

ORIC Pharmaceuticals Doses First Patients Across Expansion Arms in the P-Ib Study of ORIC-114 for the Treatment of Mutated NSCLC

Read More: ORIC Pharmaceuticals

Corcept Concludes Patient Recruitment in the P-II Study of Dazucorilant for Amyotrophic Lateral Sclerosis (ALS)

Read More: Corcept

AstraZeneca Reports Results from the P-III (TOPAZ-1) Study of Imfinzi for Treating Advanced Biliary Tract Cancer

Read More: AstraZeneca

Sanofi to Highlight New Data from the P-II Study of Frexalimab for the Treatment of Multiple Sclerosis at AAN 2024

Read More: Sanofi 

GSK to Feature Results from the P-III (ZOSTER-049) Study of Shingrix for Protection Against Shingles at ESCMID Global 2024

Read More: GSK 

Roche to Highlight the P-III (OCARINA II) Trial Results of Ocrevus for Treating Progressive and Relapsing Multiple Sclerosis at AAN 2024

Read More: Roche

GSK to Highlight Results from the P-III (EAGLE-1) Study of Gepotidacin for Treating Uncomplicated Urogenital Gonorrhoea (GC) at ESCMID 2024

Read More: GSK 

Lilly Reports the P-III (SURMOUNT-OSA) Study Data of Tirzepatide in Patients with Obstructive Sleep Apnea (OSA) and Obesity

Read More: Eli Lilly 

Artiva Biotherapeutics Doses First Patient with AlloNK in the P-I Study for Treating Lupus Nephritis

Read More: Artiva

Cerevel Therapeutics Reports Results from P-III Adjunctive Study Evaluating Tavapadon for the Treatment of Advanced Parkinson’s Disease

Read More: Cerevel

Oncternal Therapeutics Reports First Patient Dosing in Fourth Cohort of P-I/II Study of ONCT-534 for the Treatment of R/R mCRPC

Read more: Oncternal Therapeutics

Ventus Therapeutics Reports Results from the P-I Study of VENT-02 in Healthy Volunteers

Read more: Ventus Therapeutics 


Teva and Alvotech’s Selarsdi (Biosimilar, Stelara) Receives the US FDA’s Approval

Read More: Teva Pharmaceuticals


Seismic Therapeutic Highlights Preclinical Data of S-1117 for the Treatment of Autoimmune Disorders at AAN 2024

Read More: Seismic Therapeutic

Related Post:- PharmaShots Weekly Snapshots (April 08 – April 12, 2024)

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions